{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-273563","form_type":"8-K","ticker":"CPRX","cik":"0001369568","company_name":"CATALYST PHARMACEUTICALS, INC.","filed_at":"2023-11-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:28.777256+00:00","generated_at":"2026-06-08T08:58:11.401902+00:00","sec_items":["8.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Catalyst Q3 net revenues $102.7M (+79% YoY); non-GAAP EPS $0.49; raises FY revenue guidance to $390-395M","bullets":["GAAP net loss per diluted share $(0.29) reflects $81.5M one-time IPR&D expense from AGAMREE license acquisition.","Non-GAAP net income $55.9M ($0.49 diluted), up 95% YoY; total net revenues increased 79% to $102.6M.","FDA approved AGAMREE (vamorolone) for Duchenne muscular dystrophy; commercial launch expected Q1 2024.","Raised full-year 2023 total revenue guidance to $390-$395M from prior $370-$380M.","sNDA for FIRDAPSE maximum daily dose increase to 100 mg accepted for filing by FDA; two new FIRDAPSE patents allowed."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-273563","json":"https://secwatch.observer/filing/0001193125-23-273563.json","markdown":"https://secwatch.observer/filing/0001193125-23-273563.md","text":"https://secwatch.observer/filing/0001193125-23-273563.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1369568/000119312523273563/0001193125-23-273563-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1369568/000119312523273563/d581027d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T08:58:11.401902+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}